Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Case-Based Digest


      HR+ Breast Cancer

      Frontline CDK4/6 Inhibitor Selection in HR+ Breast Cancer

      May 16th 2025

      Targeted Therapies for Locally Advanced or Metastatic EGFR-mutated NSCLC

      Targeted Therapies for Locally Advanced or Metastatic EGFR-mutated NSCLC

      January 3rd 2025

      Contemporary Management Approaches for Newly Diagnosed Multiple Myeloma

      Contemporary Management Approaches for Newly Diagnosed Multiple Myeloma

      September 24th 2024

      myeloma cells

      Bispecific Antibody Therapies in Multiple Myeloma

      September 13th 2024

      Second-Line Treatment for HR+, HER2- Metastatic Breast Cancer

      Second-Line Treatment for HR+, HER2- Metastatic Breast Cancer

      July 9th 2024

      Multiple Myeloma concept and plasma cell cancer as a cancerous growth inside the bone marrow | Image Credit: © freshidea - stock.adobe.com

      CAR T-Cell Therapies for Multiple Myeloma

      May 23rd 2024

      Female reproductive system diseases.uterus cancer and endometrial malignant tumor as a uterine medical concept.3d illustration | Image Credit: © Crystal light - stock.adobe.com

      Development of Immunotherapy for Advanced Endometrial Cancer

      February 5th 2024

      Latest Conference Coverage

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.